rhIFNα-1b治疗手足口病临床分析

Clinical Analysis of α1b-Interferon for the Treatment of Hand-foot-mouth Disease

[目的]总结近4年来应用重组人干扰素α-1b（rhIFNα-1b）治疗手足口病的临床经验.[方法]回顾分析2008年4月至2011年12月期间在本院住院治疗的1301例手足口病应用rhIFNα-1b的临床疗效.[结果]发病d1~2早期应用干扰素较发病d3以后应用有更好临床疗效.出现重症手足口病表现及时联合应用大剂量丙种球蛋白及甲基强的松龙能够较好的阻断病情的进展,减少机械通气的几率.[结论]早期应用rhIFNα-1b效果较佳,出现重症表现及时联合应用大剂量丙种球蛋白及甲基强的松龙是抢救成功的关键.

[Objective] To summarize the clinical experience of αlb-interferon for the treatment of hand-foot-mouth disease in recent 4 years. [Methodsl Clinical efficacy of αlb-interferon for the treatment of 1301 hospitalized patients with hand-foot-mouth disease in our department from April 2008 to Dec. 2011 were analyzed retrospec-tively. [Results] The clinical efficacy of the early use of alb-interferon in 1-2 days at onset of the disease was better than that the use of alb-interferon at 3 days after the onset of the disease. The combination of large dose of gamma globulin and methylprednisolone for severe hand-foot-mouth disease in time could better prohibit the pro-gress of the disease and decrease the probability of mechanical ventilation. [Conclusion] The early use of αlb-inter-feron has good efficacy. The combination of large dose of gamma globulin and methylprednisolone for severe hand-foot-mouth disease in time is the key to rescue successfully.